Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Trading 03-23 14:47:19 EDT

3.57

-0.12

-3.39%

High3.74	Low3.50	Vol1.14M
Open3.72	D1 Closing3.69	Amplitude6.50%
Mkt Cap429.92M	Tradable Cap415.42M	Total Shares120.60M
T/O4.12M	T/O Rate0.98%	Tradable Shares116.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.565,"timestamp":1774291636557,"preClose":3.69,"halted":0,"volume":1138889,"delay":0,"changeRate":-0.03387533875338754,"floatShares":116528006,"shares":120595200,"eps":-0.53,"marketStatus":"Trading","change":-0.125,"latestTime":"03-23 14:47:19 EDT","open":3.72,"high":3.74,"low":3.5,"amount":4119491.3463459997,"amplitude":0.065041,"askPrice":3.57,"askSize":1310,"bidPrice":3.56,"bidSize":745,"shortable":3,"etf":0,"ttmEps":-0.53,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":3.69,"preHourTrading":{"tag":"盘前","latestPrice":3.69,"preClose":3.69,"latestTime":"08:00 EDT","volume":1006,"amount":3712.14,"timestamp":1774267208949,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.59,"preClose":3.69,"latestTime":"18:03 EDT","volume":148958,"amount":549093.7003,"timestamp":1774044231956,"change":-0.1,"changeRate":-0.0271,"amplitude":0.0271},"volumeRatio":0.906176,"impliedVol":1.1126,"impliedVolPercentile":0.3546},"requestUrl":"/m/hq/s/ACRS/wiki","defaultTab":"wiki","newsList":[{"id":"2620737928","title":"Aclaris Therapeutics to present Phase 2a ATI-2138 atopic dermatitis trial results at 2026 AAD meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620737928","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620737928?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:00","pubTimestamp":1774018837,"startTime":"0","endTime":"0","summary":"An ePoster will present results from an open-label Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor of ITK and JAK3, in patients with moderate-to-severe atopic dermatitis.The presentation is scheduled for the 2026 American Academy of Dermatology Annual Meeting and will include results not previously reported from the Phase 2a trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL2NRRs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2V16.EUR","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4007","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","ACRS","LU0314104364.USD","BK4112"],"gpt_icon":0},{"id":"2620402602","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620402602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620402602?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:22","pubTimestamp":1773922920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 08:22 ET (12:22 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2620232059","title":"Aclaris Therapeutics completes enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232059","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232059?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831315,"startTime":"0","endTime":"0","summary":"Aclaris reported completion of patient enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug  in moderate-to-severe atopic dermatitis. The study includes 109 patients and will evaluate efficacy and safety through week 24. The primary endpoint is percent change from baseline in Eczema Area and Severity Index  at week 24. Secondary endpoints at week 24 include EASI-50, EASI-75 and EASI-90 responses, plus validated Investigator Global Assessment response. Top-line results have not yet been presented and are expected in the fourth quarter of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLbZFDl8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","ACRS","SG9999014021.USD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","BK4007","IE00BN0W2T93.GBP","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2620320812","title":"Aclaris Therapeutics Inc - Top Line Results From Phase 2 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620320812","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620320812?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nTUA90RNXD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2620595255","title":"Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620595255","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620595255?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March  18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258004/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PD","TSLP","LU1878469433.USD","BK4006","AD","EASI","IE00B7SZL793.SGD","LU1169589451.USD","BK4132","BK4218","IE00B19Z4B17.USD","IGA","LU2065731478.USD","PK","ACRS","IE00B66KJ199.SGD","BK4007","BK4181","BSA","LU0963586101.USD","BK4187","LU1169590202.USD","IE0031619046.USD","ATI"],"gpt_icon":0},{"id":"2618908456","title":"Aclaris Therapeutics Raises $20 Million in Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618908456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618908456?lang=en_us&edition=fundamental","pubTime":"2026-03-12 09:13","pubTimestamp":1773277990,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics ( ($ACRS) ) has issued an announcement. On March 10, 2026, Aclaris Therapeutics, Inc. raised $20 million in gross proceeds thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-raises-20-million-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-raises-20-million-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS","EQR","BK4588","BK4585","BK4215"],"gpt_icon":0},{"id":"2618768479","title":"Aclaris Therapeutics sells 5.7 million shares for USD 20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618768479","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618768479?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:52","pubTimestamp":1773262374,"startTime":"0","endTime":"0","summary":"Aclaris sold 5.7 million shares of common stock for aggregate gross proceeds of USD 20 million under its amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. The shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbrpkP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","MNSH","BK4207","BK4007"],"gpt_icon":0},{"id":"2616342225","title":"Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342225","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342225?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539200,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., March  03, 2026   -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcasts will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/03/3248195/37216/en/Aclaris-Therapeutics-to-Participate-in-the-Leerink-Partners-2026-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","ACRS","XBI","LU0029874061.USD","LABU","HCSG","BK4007","LU0128526141.USD","XLV","BK4137","BK4588","BK4585"],"gpt_icon":0},{"id":"2614832984","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832984?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:00","pubTimestamp":1772190000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Arbor Realty Tr                                  4Q       .13   8:30 AM. ·Delek US Hldgs                                    4Q      (.19)  7:00 AM. ·NW Natural Hldg                                  4Q      1.36   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASAN","ADT","CRC","ANTA","AMR","BRCB","GSAT","BGS","BRK.B","CGEN","ANIP","CERS","CRD.B","AMWD","ASTH","AMRC","BLTE","ALG","ABR","CVEO","LIF","ARCT","NPCE","AMLX","ACEL","CORZ","AAON","ACRS","CRD.A","AZO","BEEP","CXDO","ALXO","STNE","BRK.A","BOX","ACHR","ATRA","BCYC","AMRX","CLMT","CRI","CMPX","CRCT","BTSG","BBY"],"gpt_icon":1},{"id":"2614237030","title":"Craig-Hallum Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614237030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614237030?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:56","pubTimestamp":1772117779,"startTime":"0","endTime":"0","summary":"In a report released today, Adam Vogel from Craig-Hallum reiterated a Buy rating on Aclaris Therapeutics, with a price target of $10.00. Vogel cove...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"gpt_icon":0},{"id":"2614041875","title":"Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041875","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041875?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:30","pubTimestamp":1772109002,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $1.3M, consensus $2.07M. Believes that its cash, cash equivalents and marketable securities will be sufficient to fund its opera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q4-eps-16c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-q4-eps-16c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"gpt_icon":0},{"id":"2614046960","title":"Aclaris Therapeutics Q4 EPS $(0.16) Misses $(0.14) Estimate, Sales $1.295M Miss $1.938M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046960","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046960?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:14","pubTimestamp":1772108055,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 60 percent decrease over losses of $(0.10) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50882936/aclaris-therapeutics-q4-eps-0-16-misses-0-14-estimate-sales-1-295m-miss-1-938m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2614045010","title":"Aclaris Q4 loss narrows, but misses analysts' expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045010","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045010?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:06","pubTimestamp":1772107577,"startTime":"0","endTime":"0","summary":"Aclaris Q4 loss narrows, but misses analysts' expectationsOverviewBiopharmaceutical firm Aclaris Q4 revenue and net loss missed analyst expectationsCompany reported a net loss of $19.8 mln for Q4 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2614430030","title":"BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614430030","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614430030?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:58","pubTimestamp":1772107125,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Q4 Net Income USD -19.795 Million Vs. IBES Estimate USD -17.6 Million\n\n\nFeb 26 (Reuters) - Aclaris Therapeutics Q4 revenue USD 1.295 million vs. IBES estimate USD 2.07 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX089B5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2614041713","title":"Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614041713","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614041713?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:58","pubTimestamp":1772107080,"startTime":"0","endTime":"0","summary":"- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Result","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245403/37216/en/Aclaris-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4181","BK4153","LU1169589451.USD","BK4218","BK4023","AD","AA","BK4132","BK4588","BK4007","IND","PD","BK4585","PK","ACRS"],"gpt_icon":0},{"id":"2613716653","title":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716653","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716653?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:18","pubTimestamp":1771935502,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS IN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613156417","title":"Aclaris Initiates Phase 1b Asthma Trial of Bispecific Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613156417","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613156417?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:01","pubTimestamp":1771934516,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. has initiated a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept trial evaluating ATI-052, an investigational bispecific anti-TSLP/IL-4Rα antibody, in approximately 16 asthma patients on GINA steps 2–4 therapy prior to screening. The study will assess safety, tolerability, pharmacokinetics, pharmacodynamic biomarkers , and efficacy measures such as FEV1. The company said top-line results from this asthma trial and an ongoing Phase 1b proof-of-concept trial in atopic dermatitis are expected in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL3YW1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014005.SGD","SG9999014021.USD","LU2095319765.USD","BK4112","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","ACRS","BK4007"],"gpt_icon":0},{"id":"2613771535","title":"Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Patients With Asthma With Its Novel Bispecific Anti-Tslp/Il-4RΑ Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2613771535","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613771535?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613715715","title":"Aclaris Therapeutics Inc - Phase 2B Program Encompassing Asthma and Atopic Dermatitis Expected to Start in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715715?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2613715259","title":"Aclaris Therapeutics Inc - Top Line Results Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715259?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:00","pubTimestamp":1771934401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.0424},{"period":"1month","weight":0.164},{"period":"3month","weight":0.1752},{"period":"6month","weight":0.9319},{"period":"1year","weight":1.3503},{"period":"ytd","weight":0.2259}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.038718},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.023875},{"month":4,"riseRate":0.4,"avgChangeRate":-0.010072},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction